Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bio-Rad Laboratories (NY: BIO )

460.78 +4.46 (+0.98%)
Official Closing Price Updated: 7:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 138,433
Open 452.75
Bid (Size) 440.00 (1)
Ask (Size) 515.65 (1)
Prev. Close 456.32
Today's Range 450.05 - 460.90
52wk Range 344.63 - 607.54
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
The 3 Most Promising Biotech Stocks to Buy Now
With the NIH requesting its biggest budget yet, these are the three most promising healthcare stocks to buy now. 
Via InvestorPlace
Golden Cross Appears Before Bio-Rad Laboratories Investors
 
Via Benzinga

Performance

YTD
+9.08%
+9.08%
1 Month
-5.38%
-5.38%
3 Month
+11.56%
+11.56%
6 Month
+11.16%
+11.16%
1 Year
-18.34%
-18.34%

More News

Read More
I Asked ChatGPT for 10 EV Stocks to Buy. Here’s What It Recommended.
Via InvestorPlace
Bio-Rad to Participate in Citi’s 2023 Healthcare Services, MedTech, Tools & HCIT Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Reports Fourth-Quarter and Full-Year 2022 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Earnings Scheduled For February 16, 2023
Via Benzinga
Earnings Outlook For Bio-Rad Laboratories
Via Benzinga
Cytek® Biosciences Partners with Bio-Rad to Expand Reagent Portfolios
From Cytek Biosciences, Inc.
Via Globe NewsWire
Catalent Hits Four-Month High As Danaher Reportedly Mulls A Takeover
Via Investor's Business Daily
Thoughts For Thursday: All Eyes On The CPI
Via Talk Markets
Bio-Rad to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 16, 2023
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad to Present Company Overview at J.P. Morgan 41st Annual Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio Rad Has Almost 40% Upside On Revenue Acceleration And Margin Improvement, Analyst Says
Via Benzinga
Bio-Rad To Participate in Fireside Chat During Credit Suisse’s 31st Annual Healthcare Conference
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Reports Third-Quarter 2022 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Bio-Rad to Report Third Quarter 2022 Financial Results on Thursday, October 27, 2022
From Bio-Rad Laboratories, Inc.
Via Business Wire
Why Bio-Rad Laboratories' Rumored $10 Billion Qiagen Buyout Looks Unlikely
Via Investor's Business Daily
Twitter May Drop Clickable Hashtags, AstraZeneca's Nasal COVID-19 Vaccine Fails Trial, Coinbase Gets Singapore Nod: Top Stories Tuesday, Oct. 11
Via Benzinga
Bio-Rad Laboratories, Qiagen Mull Merger Of Equals
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 25, 2022
Via Benzinga
Bio-Rad Acquires Curiosity Diagnostics
From Bio-Rad Laboratories, Inc.
Via Business Wire
Bio-Rad Laboratories: Q2 Earnings Insights
Via Benzinga
Bio-Rad Reports Second-Quarter 2022 Financial Results
From Bio-Rad Laboratories, Inc.
Via Business Wire
Tesla, Danaher And Some Other Big Gainers From Yesterday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.